NasdaqGM - Nasdaq Real Time Price USD

Wave Life Sciences, Inc. (WVE)

3.3650 +0.1450 (+4.50%)

At close: November 6 at 4:00:00 PM EST

3.4000 +0.0350 (+1.04%)

After hours: November 6 at 5:15:18 PM EST

Trade WVE on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for WVE

Previous Close 3.2200
Open 3.2500
Bid 4.2700 x 200
Ask 7.5000 x 200
Day's Range 3.2300 - 3.4200
52 Week Range 3.0400 - 21.7300
Volume 2,204,914
Avg. Volume 3,343,323
Market Cap (intraday) 663.675M
Beta (5Y Monthly) -1.44
PE Ratio (TTM) --
EPS (TTM) -1.0700
Earnings Date Oct 27, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 17.05
Zacks Rating Neutral

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

wavelifesciences.com

317

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

WVE

80.21%

S&P 500 (^GSPC)

7.76%

1-Year Return

WVE

57.30%

S&P 500 (^GSPC)

9.77%

3-Year Return

WVE

38.48%

S&P 500 (^GSPC)

68.96%

5-Year Return

WVE

28.40%

S&P 500 (^GSPC)

57.04%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q3 FY26

Revenue 13.16M

Earnings -61.91M

Profit Margin -470.53%

FY25

FY26

-60M

-40M

-20M

20M

-3000.0%

-2000.0%

-1000.0%

Analyst Price Targets

10.00

17.05 Average

3.3650 Current

44.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 10/29/2026

Analyst Canaccord Genuity

Rating Action Maintains

Rating Buy

Price Action Raises

Price Target 42 -> 44

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

-296.86%
Return on Assets (ttm)

-37.97%
Return on Equity (ttm)

-78.80%
Revenue (ttm)

70.92M
Net Income Avi to Common (ttm)

-210.53M
Diluted EPS (ttm)

-1.0700

Balance Sheet and Cash Flow

Total Cash (mrq)

430.75M
Total Debt/Equity (mrq)

10.77%
Levered Free Cash Flow (ttm)

-132.66M

VYGR Voyager Therapeutics, Inc.

1.8650 +6.40%

SRRK Scholar Rock Holding Corporation

46.94 +3.16%

CTMX CytomX Therapeutics, Inc.

2.1900 +2.34%

SLDB Solid Biosciences Inc.

6.59 +8.74%

RGNX REGENXBIO Inc.

7.62 +3.25%

U.S. markets closed

Wave Life Sciences, Inc. (WVE)

Trading disclosure

-6.27%

-4.40%

-53.84%

-80.21%

-57.30%

-28.40%

-80.26%

Wave Life Sciences, Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch